- Home
- JSPR vs ANVS Comparison
JSPR vs ANVS Comparison
Compare JSPR & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ANVS
- Stock Information
- Founded
- JSPR 2018
- ANVS 2008
- Country
- JSPR United States
- ANVS United States
- Employees
- JSPR 64
- ANVS N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ANVS Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- ANVS Health Care
- Exchange
- JSPR Nasdaq
- ANVS Nasdaq
- Market Cap
- JSPR 47.6M
- ANVS 55.5M
- IPO Year
- JSPR N/A
- ANVS 2020
- Fundamental
- Price
- JSPR $2.86
- ANVS $2.61
- Analyst Decision
- JSPR Buy
- ANVS Strong Buy
- Analyst Count
- JSPR 12
- ANVS 4
- Target Price
- JSPR $30.78
- ANVS $18.00
- AVG Volume (30 Days)
- JSPR 293.2K
- ANVS 265.4K
- Earning Date
- JSPR 08-13-2025
- ANVS 08-12-2025
- Dividend Yield
- JSPR N/A
- ANVS N/A
- EPS Growth
- JSPR N/A
- ANVS N/A
- EPS
- JSPR N/A
- ANVS N/A
- Revenue
- JSPR N/A
- ANVS N/A
- Revenue This Year
- JSPR N/A
- ANVS N/A
- Revenue Next Year
- JSPR N/A
- ANVS N/A
- P/E Ratio
- JSPR N/A
- ANVS N/A
- Revenue Growth
- JSPR N/A
- ANVS N/A
- 52 Week Low
- JSPR $2.27
- ANVS $1.11
- 52 Week High
- JSPR $26.05
- ANVS $10.54
- Technical
- Relative Strength Index (RSI)
- JSPR 42.31
- ANVS 47.43
- Support Level
- JSPR $2.90
- ANVS $2.58
- Resistance Level
- JSPR $3.14
- ANVS $2.94
- Average True Range (ATR)
- JSPR 0.20
- ANVS 0.18
- MACD
- JSPR 0.09
- ANVS -0.01
- Stochastic Oscillator
- JSPR 71.03
- ANVS 41.86
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.